Abstract: The invention relates to small cholestyramine pellets that can be prepared by extrusion. The pellets have a high cholestyramine loading and are stable enough to be coated with one or more coating layers. The invention also relates to a process for the preparation of such pellets and to a multiparticulate drug delivery system comprising such pellets.
Type:
Grant
Filed:
March 3, 2017
Date of Patent:
October 15, 2019
Assignee:
Albireo AB
Inventors:
Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.
Type:
Grant
Filed:
March 3, 2017
Date of Patent:
October 15, 2019
Assignee:
Albireo AB
Inventors:
Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Type:
Grant
Filed:
May 10, 2018
Date of Patent:
March 5, 2019
Assignee:
Albireo AB
Inventors:
Per-Göran Gillberg, Hans Graffner, Ingemar Starke
Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Type:
Grant
Filed:
October 5, 2017
Date of Patent:
July 3, 2018
Assignee:
Albireo AB
Inventors:
Per-Göran Gillberg, Hans Graffner, Ingemar Starke
Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Type:
Grant
Filed:
October 2, 2017
Date of Patent:
June 19, 2018
Assignee:
Albireo AB
Inventors:
Per-Göran Gillberg, Hans Graffner, Ingemar Starke
Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Type:
Grant
Filed:
September 26, 2016
Date of Patent:
July 4, 2017
Assignee:
Albireo AB
Inventors:
Per-Göran Gillberg, Hans Graffner, Ingemar Starke
Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Type:
Grant
Filed:
March 14, 2016
Date of Patent:
June 27, 2017
Assignee:
Albireo AB
Inventors:
Per-Göran Gillberg, Hans Graffner, Ingemar Starke
Abstract: The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl)propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl)propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methyl or ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them.
Type:
Grant
Filed:
June 11, 2014
Date of Patent:
November 10, 2015
Assignee:
Albireo AB
Inventors:
Anders Broo, Johan Gottfries, Michael Kossenjans, Li Lanna, Eva-Lotte Lindstedt-Alstermark, Kristina A. Nilsson, Bengt Ohlsson, Maria Thorstensson, Maria Boije
Abstract: The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl)propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl)propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methyl or ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them.
Type:
Grant
Filed:
March 11, 2011
Date of Patent:
July 22, 2014
Assignee:
Albireo AB
Inventors:
Anders Broo, Johan Gottfries, Michael Kossenjans, Li Lanna, Eva-Lotte Lindstedt-Alstermark, Kristina A. Nilsson, Bengt Ohlsson, Maria Thorstensson, Per Olof Sjögren
Abstract: The present invention relates to a combination comprising a substance with inhibiting effect on the ileal bile acid transport system (I BAT) and at least one other active substance selected from an IBAT inhibitor; an enteroendocrine peptide or enhancer thereof; a dipeptidyl peptidase-IV inhibitor; a biguanidine; an incretin mimetic; a thiazolidinone; a PPAR agonist; a HMG Co-A reductase inhibitor; a bile acid binder; and a TGR5 receptor modulator; wherein the IBAT inhibitor compound and the at least one other active substance are administered simultaneously, sequentially or separately.
Type:
Application
Filed:
November 8, 2011
Publication date:
September 12, 2013
Applicant:
Albireo AB
Inventors:
Per-Göran Gillberg, Hans Graffner, Ingemar Starke
Abstract: The present invention relates to new substituted azetidine compounds of formula (I): or pharmaceutically acceptable salts thereof, as further described herein, to pharmaceutical compositions containing them, and the use of the compounds in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia. The compounds are neurokinin (NK) antagonists. The present invention further relates to processes for the preparation of the compounds.
Type:
Grant
Filed:
September 27, 2006
Date of Patent:
October 16, 2012
Assignee:
Albireo AB
Inventors:
Rolf Bergman, Sara Holmqvist, Sverker Von Unge
Abstract: The present invention regards specific IBAT inhibitors with improved effect in prophylaxis and treatment of metabolic syndrome, obesity, disorders of fatty acid metabolism, glucose utilization disorders, disorders in which insulin resistance is involved, diabetes mellitus, type 1 and type 2 diabetes. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Type:
Application
Filed:
May 26, 2011
Publication date:
May 10, 2012
Applicant:
ALBIREO AB
Inventors:
Ingemar Starke, Hans Graffner, Per-Göran Gillberg, Ann-Margret Lindqvist, Bo Angelin
Abstract: The present invention relates to new compounds of formula I, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of compounds of formula I.
Type:
Grant
Filed:
May 11, 2007
Date of Patent:
January 31, 2012
Assignee:
Albireo AB
Inventors:
Anders Johansson, Johan Johansson, Carl-Gustav Sigfridsson
Abstract: Compounds of formula: (1) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
Type:
Grant
Filed:
February 23, 2004
Date of Patent:
November 29, 2011
Assignee:
Albireo AB
Inventors:
Ingemar Starke, Suzanne Alenfalk, Mats Peter Nordberg, Mikael Ulf Johan Dahlstrom, Stig Jonas Bostrom, Malin Anita Lemurell, Andreas Christer Wallberg
Abstract: The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl)propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl)propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methyl or ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them.
Type:
Application
Filed:
March 11, 2011
Publication date:
July 7, 2011
Applicant:
ALBIREO AB
Inventors:
Anders Broo, Johan Gottfries, Michael Kossenjans, Li Lanna, Eva-Lotte Lindstedt-Alstermark, Kristina A. Nilsson, Bengt Ohlsson, Maria Thorstensson, Maria Boije, Per Olof Sjögren
Abstract: The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl) propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl) propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methylor ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them.
Type:
Application
Filed:
March 7, 2008
Publication date:
January 27, 2011
Applicant:
ALBIREO AB
Inventors:
Anders Broo, Johan Gottfries, Michael Kossenjans, Li Lanna, Eva-Lotte Lindstedt-Alstermark, Kristina A. Nilsson, Bengt Ohlsson, Maria Thorstensson, Maria Boije, Olof Sjogren
Abstract: A method of treatment of functional constipation or C-IBS in a warm-blooded animal is disclosed, which comprises the administration of an IBAT inhibitor.
Type:
Grant
Filed:
April 1, 2004
Date of Patent:
April 7, 2009
Assignee:
Albireo AB
Inventors:
Hasse Roland Abrahamsson, Per-Goran Gillberg
Abstract: The present invention relates to a compound of the general formula (I) wherein Het is an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring having at least one nitrogen atom; R1 is hydrogen, hydroxy, C1-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl or C2-C4 alkynyl; R2 and R3 is each and independently selected from hydrogen, C1-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 alkoxy, halogen and cyano, provided that R2 and R3 may not both be hydrogen; R4 is C1-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl or C2-C4 alkynyl; Ar is an optionally substituted aromatic ring system selected from pyridinyl; 1-naphthyl; 5,6,7,8-tetrahydro-1-naphthyl; quinolinyl; 2,3-dihydro-1,4-benzodioxinyl; 1,3-benzodioxolyl; 5,6,7,8-tetrahydroquinolinyl; 5,6,7,8-tetrahydroisoquinolinyl; 5,6,7,8-tetrahydroquinazolin-4-yl; 1-benzo[b]thiophen-7-yl; 1-benzo[b]thiophen-4-yl; 1-benzo[b]thiophen-3-yl; isoquinolinyl; quinazolinyl; and indan-4-yl; or Ar is substituted phenyl; or an enantiomer thereof or any salt thereo